Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.
about
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease.Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment.A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.Robust fit of Bayesian mixed effects regression models with application to colony forming unit count in tuberculosis research.Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.Detecting Phenotypically Resistant Mycobacterium tuberculosis Using Wavelength Modulated Raman Spectroscopy.Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model.The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trialUsing biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
P2860
Q28602112-36406E29-8D71-4335-896A-A5377336FA9DQ36100081-20283972-4C6C-4CD1-9642-B3618AA08510Q40075546-DFC62017-8C28-444F-8CAF-3297F7A09433Q42588101-79864148-D278-4C50-A7AB-03C6B1AACBB0Q42938895-A3C90417-48BE-4526-83A3-1052A1195A6EQ46046130-7A4AA04E-41A0-491E-A293-88FCC61A88D5Q46921427-13B7724A-0DBB-43C3-85A9-89E44667676EQ47104871-138BE63E-5BD3-4FE3-9788-A43DA7C588BFQ50097384-0270C26A-C8FF-4A9E-83ED-9D13978191BAQ52584723-37996C0A-8A5B-4103-98DF-D4CDB4ECAD2FQ52663222-F28C815D-A6B6-4199-884B-A5B5BAB38BB9Q55232003-0D1BC066-5C22-49B9-B340-7CD469246C66Q56395625-9E2D1C1D-1E18-4FCC-A358-5FCB79611978Q57276328-42F01FC6-1D61-4BC1-B752-0E6C748C517B
P2860
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Limited role of culture conver ...... confirmatory clinical trials.
@ast
Limited role of culture conver ...... confirmatory clinical trials.
@en
type
label
Limited role of culture conver ...... confirmatory clinical trials.
@ast
Limited role of culture conver ...... confirmatory clinical trials.
@en
prefLabel
Limited role of culture conver ...... confirmatory clinical trials.
@ast
Limited role of culture conver ...... confirmatory clinical trials.
@en
P2093
P2860
P50
P1433
P1476
Limited role of culture conver ...... confirmatory clinical trials.
@en
P2093
Andreas H Diacon
Andrew J Nunn
Angela M Crook
Carl M Mendel
Rodney Dawson
P2860
P2888
P356
10.1186/S12916-016-0565-Y
P407
P577
2016-02-04T00:00:00Z
P5875
P6179
1045419948